In utero beta-2-adrenergic agonists exposure and risk of epilepsy: A Danish nationwide population-based cohort study.

In utero exposure to β2AAs, particularly in the first or second trimesters, may be associated with an increased risk of epilepsy. It may partly be due to the indication of β2AAs use, but a direct effect of β2AAs cannot be ruled out.